Excellence in Research webinar series
Your trusted resource for the world’s largest and most diverse collection of human and animal cell lines, microorganisms, biological products, standards, and custom services announces the 2016 Excellence in Research webinar series. The series will showcase the implementation of leading technologies, the importance of standards, and the application of new ATCC products and services to advance your scientific research. The webinars will broadcast live for 30 to 45 minutes and will be followed by a 10 minute question and answer period. Register to join the webinar that best meets your schedule.
Functionally Characterized Human PBMCs: An Improved In Vitro Model of Human Immune Response
Alexei Miagkov, Ph.D., Senior Scientist, Immunology, ATCC
June 30, 2016
Abstract: Human Peripheral Blood Mononuclear Cells (PBMCs) contain many of the functional cell types of immune system, and are an ideal model to study the human immune response in vitro. Currently, PBMCs are being used in basic and clinical research areas including basic immunology and cell biology, infectious diseases, vaccine development, tumor immunology, and drug discovery. PBMC are also widely used for monitoring disease progression, designing personalized approaches to treatment, and predicting the occurrence of treatment-associated adverse events. The majority of PBMC applications rely on highly complex cell-based assays; however, phenotypic and functional variability of human PBMCs makes the development and validation of these assays difficult. Additionally, variations in cell collection and cryopreservation protocols can further affect PBMC properties. In this presentation, we demonstrate that pre-screening characterization of lot-specific functional activity of PBMCs is extremely useful for selecting cells to address individual experimental goals.
- PBMCs play a critical role in modern biomedical research; however, the functional activity of these cells is highly variable
- Many factors affecting PBMC variability, including genetic diversity and environmental pressure, are outside of researchers’ control
- Conducting pre-screening and establishing PBMC functional activity profiles offers an attractive solution to address PBMC variability
Biography: Alexei Miagkov leads the Tumor Immunology group at ATCC Cell Systems. Prior to joining ATCC, Dr. Miagkov served as the Scientific Program Manager at PerkinElmer, where he was responsible for the design, validation, and implementation of assays intended for preclinical studies in oncology and inflammatory diseases. He also held progressing scientific roles at Caliper Life Sciences and NovaScreen Biosciences. Dr. Miagkov completed a post-doctoral fellowship in neuro-immunology at Johns Hopkins University, and earned his Ph.D. in cell biology and M.S. in cellular immunology and microbiology from Moscow State University.
Register for a session 10:00 AM or 3:00 PM ET.
Browse and view past webinars ON DEMAND
- Free online cell culture and assay training webinars